Chemours Company (The) (CC) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Chemours Company (The) (NYSE:CC) have earned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $57.29.

Several research firms have recently issued reports on CC. Barclays PLC raised their price objective on Chemours Company (The) from $55.00 to $58.00 and gave the stock an “overweight” rating in a report on Monday. Zacks Investment Research cut Chemours Company (The) from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. UBS AG raised Chemours Company (The) from a “sell” rating to a “neutral” rating and raised their price objective for the company from $36.00 to $50.00 in a research report on Monday, August 7th. J P Morgan Chase & Co raised their price objective on Chemours Company (The) to $55.00 and gave the company an “overweight” rating in a research report on Friday, August 4th. Finally, Argus reaffirmed a “buy” rating and set a $55.00 target price (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th.

In other news, VP Amy Trojanowski sold 2,500 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $46.03, for a total transaction of $115,075.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David C. Shelton sold 5,908 shares of the company’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $56.01, for a total transaction of $330,907.08. Following the transaction, the senior vice president now directly owns 47,356 shares of the company’s stock, valued at approximately $2,652,409.56. The disclosure for this sale can be found here. Insiders sold 77,142 shares of company stock valued at $3,953,265 over the last quarter. 1.14% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC increased its holdings in shares of Chemours Company (The) by 3.4% during the second quarter. Acrospire Investment Management LLC now owns 3,076 shares of the specialty chemicals company’s stock worth $117,000 after buying an additional 100 shares in the last quarter. Charter Trust Co. boosted its stake in Chemours Company (The) by 2.1% in the second quarter. Charter Trust Co. now owns 5,720 shares of the specialty chemicals company’s stock valued at $217,000 after acquiring an additional 120 shares during the last quarter. Cypress Capital Management LLC boosted its stake in Chemours Company (The) by 0.5% in the second quarter. Cypress Capital Management LLC now owns 31,393 shares of the specialty chemicals company’s stock valued at $1,190,000 after acquiring an additional 155 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Chemours Company (The) by 0.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,921 shares of the specialty chemicals company’s stock valued at $1,021,000 after acquiring an additional 167 shares during the last quarter. Finally, Commerce Bank raised its holdings in Chemours Company (The) by 3.0% in the second quarter. Commerce Bank now owns 7,158 shares of the specialty chemicals company’s stock worth $272,000 after purchasing an additional 206 shares during the period. 73.23% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Chemours Company (The) (CC) Receives Consensus Recommendation of “Buy” from Analysts” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/06/chemours-company-the-cc-receives-consensus-recommendation-of-buy-from-analysts.html.

Chemours Company (NYSE:CC) traded down $0.14 during trading on Monday, reaching $52.02. The company’s stock had a trading volume of 3,103,620 shares, compared to its average volume of 1,994,542. Chemours Company has a 52 week low of $16.39 and a 52 week high of $58.08. The company has a quick ratio of 1.63, a current ratio of 2.19 and a debt-to-equity ratio of 5.07. The firm has a market cap of $9,658.11, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.93 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last released its quarterly earnings data on Thursday, November 2nd. The specialty chemicals company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.11. Chemours Company (The) had a return on equity of 116.80% and a net margin of 4.86%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same period last year, the business posted $0.61 EPS. Chemours Company (The)’s quarterly revenue was up 13.3% on a year-over-year basis. equities analysts predict that Chemours Company will post 3.63 EPS for the current year.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

What are top analysts saying about Chemours Company (The)? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemours Company (The) and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit